Raymond James Financial Inc. Takes $27.01 Million Position in Hologic, Inc. (NASDAQ:HOLX)

Raymond James Financial Inc. purchased a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 374,641 shares of the medical equipment provider's stock, valued at approximately $27,007,000. Raymond James Financial Inc. owned approximately 0.17% of Hologic as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the business. Geode Capital Management LLC increased its holdings in shares of Hologic by 2.6% in the 4th quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider's stock worth $412,159,000 after buying an additional 144,838 shares during the last quarter. Victory Capital Management Inc. lifted its stake in Hologic by 0.5% during the fourth quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider's stock worth $354,506,000 after purchasing an additional 24,358 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of Hologic by 3.0% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider's stock worth $322,272,000 after purchasing an additional 129,035 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Hologic by 16.4% during the 4th quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider's stock valued at $293,434,000 after buying an additional 572,187 shares in the last quarter. Finally, Boston Partners lifted its position in Hologic by 81.0% in the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock worth $257,959,000 after buying an additional 1,602,463 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Analyst Upgrades and Downgrades

HOLX has been the subject of a number of recent research reports. Royal Bank of Canada lowered their price objective on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a report on Thursday, February 6th. Needham & Company LLC lowered shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 price target for the company. in a research report on Monday, February 3rd. Argus downgraded Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Raymond James restated an "outperform" rating and set a $90.00 target price (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. Finally, Citigroup decreased their price target on Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Eleven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Hologic has a consensus rating of "Hold" and an average target price of $84.62.

Hologic Stock Performance

Shares of NASDAQ:HOLX traded up $0.54 during trading on Wednesday, hitting $58.73. The company's stock had a trading volume of 334,733 shares, compared to its average volume of 1,949,178. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The firm has a market cap of $13.18 billion, a price-to-earnings ratio of 18.53, a P/E/G ratio of 2.14 and a beta of 0.82. The company has a 50-day moving average of $61.34 and a 200-day moving average of $70.45. Hologic, Inc. has a 12 month low of $55.89 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.